ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

GSK Gsk Plc

1,599.00
15.50 (0.98%)
19 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Gsk Plc LSE:GSK London Ordinary Share GB00BN7SWP63 ORD 31 1/4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  15.50 0.98% 1,599.00 1,599.50 1,600.50 1,600.00 1,575.00 1,579.50 5,149,016 16:35:14
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 30.33B 4.93B 1.1970 13.37 65.87B
Gsk Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker GSK. The last closing price for Gsk was 1,583.50p. Over the last year, Gsk shares have traded in a share price range of 1,302.60p to 1,719.80p.

Gsk currently has 4,117,033,438 shares in issue. The market capitalisation of Gsk is £65.87 billion. Gsk has a price to earnings ratio (PE ratio) of 13.37.

Gsk Share Discussion Threads

Showing 32826 to 32849 of 33100 messages
Chat Pages: 1324  1323  1322  1321  1320  1319  1318  1317  1316  1315  1314  1313  Older
DateSubjectAuthorDiscuss
11/1/2024
10:55
#Anhar, indeed, I re-bought my missing 20% post consolidation which my spreadsheet had failed to account for, it is the total costs (less total dividends received) vs the total value of the 2 combined today to give the correct adjusted P/L..

Talking of dividends has anybody received their credit today yet..?

laurence llewelyn binliner
11/1/2024
10:11
MHRANGOON is correct that you have to adjust for the consolidation in order to compare current values with the pre-demerger value. You can't just look at the share prices alone to make a comparison with the pre-demerger value, you need to consider the number of shares involved.

The terms were that pre-demerger GSK holders received 1 HLN for every 1 GSK share held. Following that, GSK shares were consolidated at 4 for 5.

So assume for example you held 1,000 old GSK, then you would now have 1,000 HLN and 800 current GSK.

Using the above figures, the old GSK share price of 1,800p gives a value of £18,000 pre-dem.

With new GSK now at 1,570p the holding is worth £12,560 and HLN £3,370, a total of £15,930 which is a loss of £2,070 or 11.5% on the old GSK value. Clearly then, the combined holding would have to rise to £18,000 just to break even, which could be satisfied by GSK or HLN alone or some combination of the two.

anhar
11/1/2024
09:50
It was a 1:1 HLN:GSK share allocation then a 20% consolidation after..

I bought my 20% GSK back again to keep my numbers as they were, but great to see the share price recovering well now 12-18 months later from the lows of 1300 after the consolidation..

Next dividend payment due today too so there should be some DRIP buying as they roll in.. :o)

laurence llewelyn binliner
11/1/2024
09:34
I think it was calculated so that the HLN share capital issue was worth 20% of the value of the old combined GSK.But I would be very happy to exit somewhere between 18 and 19 quid
rikky72
11/1/2024
06:40
I dont think this formula is correct as total number of share allocation reduced.
mhrangoon
10/1/2024
18:17
The pre split share price in summer 2022 was about 1800, and with the share price today at 1570, plus the HLN share price of 337 gives us c1900 total, so we are ahead again at last 18 months later..

GSK at 1800 stand alone would be great to see with HLN alongside adding value for those holders who kept them, as soon as they hit their debt to EBITDA ratio the dividend will pick up pace there too..

laurence llewelyn binliner
10/1/2024
11:11
DB raises target price to 1850p from 1750p
dplewis1
10/1/2024
08:04
GSK, a pharmaceutical group, said Nucala (mepolizumab) has been approved in China for use in severe asthma with an eosinophilic phenotype.
mj19
09/1/2024
16:15
GSK exec says well on track to hit all targets company set out for 2026 - JPM healthcare conference
dplewis1
09/1/2024
12:07
Money moved to APH , great dividend yields & excellent healthcare company
blackhorse23
09/1/2024
09:09
Big pharma just gets that bit bigger.

Good luck all 👍🏻

tuftymatt
09/1/2024
08:06
GSK said it bought biopharmaceutical company Aiolos Bio for an upfront consideration of $1.0 billion and the potential for an additional $400 million, the latest in a string of pharmaceutical majors buying fast-growing biotechs to restock their pipelines.

The British pharmaceutical giant said Tuesday that the deal to buy San Francisco and London-based Aiolos Bio, which focuses on patients with respiratory and inflammatory conditions, includes a Phase 2-ready antibody called AIO-001 for the treatment of adult patients with certain respiratory and inflammatory conditions.

The portfolio addition "could expand the reach of our current respiratory biologics portfolio, to the 40% of severe asthma patients with low type 2 inflammation where treatment options are still needed," Chief Scientific Officer Tony Wood said.

The additional payment of up to $400 million is dependent on certain regulatory milestones being met, it said.

tradermichael
06/1/2024
11:24
12/2023 Q3 Dividend:
Pays next Thursday 11-Jan-24 (14p/share)

tradermichael
04/1/2024
09:55
I hope you are right but personally I think that may be a bit of a stretch.

This year though I wouldn't bet against.

Good luck all 👍🏻

tuftymatt
04/1/2024
09:35
Hopefully this momentum can be maintained, and reach £17 by end of month
alibizzle
03/1/2024
12:03
I think that Jefferies loves GSK nearly as much as I do ..... ;0)
tradermichael
03/1/2024
10:55
GSK: Stock price offers attractive risk remuneration, according to Jefferies -- Market TalkSource: MF Dow Jones (English)Original article published in Dow Jones English Newswire, translated by Il Sole 24 Ore Radiocor editorial staff.(Il Sole 24 Ore Radiocor Plus) - Milan, 3 Jan - ? GSK is expected to give at least one-digit EPS growth guidance for 2024 and resolve the Zantac litigation case within the next few months, Jefferies analysts write in a note raising the rating on the buy-to-hold stock.Analysts estimate the pharmaceutical company will pay between $3 billion and $4 billion to resolve the case.The company's growth profile is undervalued and the current share price offers an attractive risk remuneration.Jefferies raised the stock's target price to 1,900 pence from 1,550 pence. Stocks are currently up 2.2% and 4.3% in the last 12 months. (ian.walker@wsj.com.)(END) Dow Jones NewswiresJanuary 03, 2024 03:50 ET (08:50 GMT)Copyright (c) 2024 Dow Jones-Radiocor
patientcapital
03/1/2024
10:19
The following is an extract from the article: -

GSK’s revival ‘will become clear to investors in 2024’

...


“When we meet investors, the things that they say to us are, ‘We want to see visible progress in the pipeline.’ So that’s readouts and we’ve got a number of those coming up next year in oncology and respiratory, as well as infectious diseases.”

They include hopes for Blenrep, a blood cancer treatment, which produced encouraging trial results in November, a year after it had suffered a clinical setback. “If we can show that there’s a pathway back to the market, this is an important element for our credibility,” Miels said

Another is depemokimab, a twice-yearly injection to treat asthma and other respiratory diseases, and camlipixant, a potential treatment for refractory chronic cough, taken as a twice-daily pill. Both are potential blockbusters, or drugs that generate annual sales of at least $1 billion for their company, in late-stage development.

GSK has been bolstering its late-stage pipeline through bolt-on and licensing deals, including agreements in October and December for cancer drugs developed by Hansoh Pharma, of China.

...

pj84
03/1/2024
10:10
Walmsley is in the DM today as well.
patientcapital
03/1/2024
09:58
Try using or
zho
03/1/2024
09:56
Anyone know what the TIMES said about GSK, please?
tradermichael
03/1/2024
09:18
My choice for 2024, GSK, Bats, Phoenix for nice dividends and one growth share Fortinet Inc on Nasdaq.GLA for 2024.
montyhedge
03/1/2024
09:03
Still cheap this year should take us to £20
mj19
03/1/2024
08:51
GSK is expected to guide for at least low single digit EPS growth for 2024 and settle the Zantac litigation case within the coming months, Jefferies analysts write in a research note as they raise their rating on the stock to buy from hold. They estimate that the pharma company will pay between $3bn and $4bn to settle the case. The company's growth profile is under appreciated and the current share price offers attractive risk reward.
dplewis1
Chat Pages: 1324  1323  1322  1321  1320  1319  1318  1317  1316  1315  1314  1313  Older

Your Recent History

Delayed Upgrade Clock